Search

Mark Puder Phones & Addresses

  • 22 Boyden Rd, Medfield, MA 02052 (508) 359-8545
  • 2 High St, Medfield, MA 02052
  • 32 Wight St, Medfield, MA 02052 (508) 359-8545
  • 61 Addington Rd, West Roxbury, MA 02132
  • Boston, MA
  • Wichita Falls, TX
  • 22 Boyden Rd, Medfield, MA 02052 (508) 612-2348

Work

Company: Childrens Hospital PDS Address: 300 Longwood Ave, Boston, MA 02115 Phones: (617) 355-2469

Education

School / High School: Vanderbilt University School Of Medicine 1986

Languages

English

Awards

Healthgrades Honor Roll

Ranks

Certificate: General Surgery, 2000

Emails

Specialities

Pediatric Surgery

Professional Records

Medicine Doctors

Mark Puder Photo 1

Dr. Mark Puder, Boston MA - MD (Doctor of Medicine)

View page
Specialties:
Pediatric Surgery
Address:
Childrens Hospital PDS
300 Longwood Ave, Boston, MA 02115
(617) 355-2469 (Phone)
Certifications:
General Surgery, 2000
Pediatric Surgery, 2011
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Medical School
Vanderbilt University School Of Medicine
Graduated: 1986
Medical School
Yale New Haven Hospital
Graduated: 1987
Medical School
Beth Israel Deaconess Hospital
Graduated: 1999
Medical School
New England Deaconess Hospital
Graduated: 1991
Medical School
Yale New Haven Hospital
Graduated: 1988
Medical School
Boston Chldns Hospital
Graduated: 2001
Mark Puder Photo 2

Mark Puder

View page
Specialties:
Pediatric Surgery
Work:
Boston Childrens Hospital General Surgery
300 Longwood Ave, Boston, MA 02115
(617) 355-2469 (phone), (617) 730-0477 (fax)
Education:
Medical School
Vanderbilt University School of Medicine
Graduated: 1986
Procedures:
Appendectomy
Hernia Repair
Thoracoscopy
Conditions:
Appendicitis
Languages:
English
Spanish
Description:
Dr. Puder graduated from the Vanderbilt University School of Medicine in 1986. He works in Boston, MA and specializes in Pediatric Surgery. Dr. Puder is affiliated with Boston Childrens Hospital.
Mark Puder Photo 3

Mark Puder, Boston MA

View page
Specialties:
Surgery
Pediatric Surgery
Thoracic Surgery
Cardiothoracic Vascular Surgery
Work:
Children's Hospital
300 Longwood Ave, Boston, MA 02115
Education:
Vanderbilt University (1986)
Mark Puder Photo 4

Mark Puder, Boston MA

View page
Specialties:
Pediatric Surgeon
Address:
300 Longwood Ave, Boston, MA 02115
Board certifications:
American Board of Surgery Certification in Surgery
American Board of Surgery Sub-certificate in Pediatric Surgery (Surgery)

Business Records

Name / Title
Company / Classification
Phones & Addresses
Mark Puder
Mark Puder MD
Thoracic Surgery · Surgeons · Pediatric Surgeon
300 Longwood Ave, Boston, MA 02115
(617) 355-2469

Publications

Us Patents

Method Of Treating Fatty Liver Disease

View page
US Patent:
7897591, Mar 1, 2011
Filed:
Jul 28, 2006
Appl. No.:
11/997002
Inventors:
Mark Puder - Medfield MA,
Marsha A. Moses - Brookline MA,
Assignee:
Children's Medical Center Corporation - Boston MA
International Classification:
A01N 43/00
A61K 37/18
US Classification:
514183, 514154
Abstract:
The present invention relates to a method for treating a fatty liver disease or disorder in a patient in need thereof. The method comprises administering at least one matrix metalloproteinase (“MMP”) inhibitor to the patient. Fatty liver disease or disorders include, for example, NAFLD, NASH, ALD, fatty liver associated with chronic hepatitis infection, TPN, steroid treatment, tamoxifen treatment, gastrointestinal operations, diabetes and Reye's Syndrome. The method is particularly useful when the fatty liver disease is associated with TPN and the patient is an infant or when the patient is obese. MMP inhibitors useful in the present invention include, for example, Marimastat, tetracyclines, Prinomastat, Batimastat, BAY 12-9566, AG3340, BMS-275291, Neovastat, BB-3644, KB-R7785, TIMP1, TIMP2, doxycycline, minocycline, RS-130,830; CGS 27023A, Solimastat, Ro 32-3555, BMS-272591, and D2163. Marimastat is a preferred MMP inhibitor.

Prevention Of Surgical Adhesions Using Selective Cox-2 Inhibitors

View page
US Patent:
2004022, Nov 4, 2004
Filed:
Jan 29, 2004
Appl. No.:
10/767870
Inventors:
Mark Puder - Medfield MA,
Arin Greene - Wellesley MA,
Judah Folkman - Brookline MA,
Assignee:
Children's Medical Center Corporation - Boston MA
International Classification:
A61K031/415
US Classification:
514/406000, 424/422000, 514/403000
Abstract:
The present invention provides a method for the minimization or prevention of adhesion formation during or following a surgical procedure. The method comprises administering to the patient in need thereof a therapeutically effective amount of at least one COX-2 inhibitor, wherein the COX-2 inhibitor is not nimesulide. The COX-2 inhibitor can be administered before, during, or after surgery. In a preferred embodiment, the COX-2 inhibitor is celecoxib, also known as Celebrex (Pfizer).

Treatment And Prevention Of Liver Disease Associated With Parenteral Nutrition (Pn)

View page
US Patent:
2006012, Jun 15, 2006
Filed:
Nov 4, 2005
Appl. No.:
11/267663
Inventors:
Mark Puder - Medfield MA,
Kathleen Gura - Norfolk MA,
Assignee:
Children's Medical Center Corporation - Boston MA
International Classification:
A61K 35/60
A61K 31/202
US Classification:
424523000, 514560000
Abstract:
The present invention is based on the discovery that parenteral nutrition (PN) induced liver disease, e.g. fatty liver disease, can be prevented and even reversed by administration of primarily omega-3-fatty acid with PN rather than the administration of the standard intravenous lipid emulsions that contain primarily plant derived omega-6 fatty acid. Thus, the present invention provides a method for treating or preventing liver disease in a human patient obtaining nutritional support through PN. The method comprises intravenous administration of an effective amount of an omega-3-fatty acid emulsion to the patient, wherein the patient is not administered phytosterols or plant derived fatty acids, e.g. omega-6 fatty acids derived from a plant source, and wherein the administration of the omega-3-fatty acid emulsion to the patient is for a period greater than three weeks. Preferably, the administration is for a period of greater than six weeks. More preferably, the administration is for a period greater than three months.

Patient-Friendly Stethoscope

View page
US Patent:
2006026, Nov 23, 2006
Filed:
May 22, 2006
Appl. No.:
11/438599
Inventors:
Mark Puder - Medfield MA,
Assignee:
Children's Medical Center Corporation - Boston MA
International Classification:
A61B 7/02
US Classification:
181131000
Abstract:
Generally, the present invention is directed to medical devices and more particularly to a patient-friendly stethoscope with interactive light emissions. An embodiment of the invention includes a stethoscope which has a pair of binaurals and a transparent acoustical tubing connecting the binaurals to the chestpiece. An optical fiber is located within the transparent acoustical tubing extending from the junction region of the tubing to and within the chestpiece, thereby illuminating the chestpiece, the rim of the diaphragm and bell, and attachments to the chestpiece. The optical fiber has a light source coupled at its proximal end thereby illuminating the transparent acoustical tubing, the chestpiece, and attachments thereto from within.

Treatment And Prevention Of Liver Disease Associated With Parenteral Nutrition (Pn)

View page
US Patent:
2008027, Nov 6, 2008
Filed:
Jul 1, 2008
Appl. No.:
12/165785
Inventors:
Mark Puder - Medfield MA,
Kathleen M. Gura - Norfolk MA,
Assignee:
CHILDREN'S MEDICAL CENTER CORPORATION - Boston MA
International Classification:
A61K 31/202
A61P 1/16
US Classification:
514560
Abstract:
The present invention is based on the discovery that parenteral nutrition (PN) induced liver disease, e.g. fatty liver disease, can be prevented and even reversed by administration of primarily omega-3-fatty acid with PN rather than the administration of the standard intravenous lipid emulsions that contain primarily plant derived omega-6 fatty acid. Thus, the present invention provides a method for treating or preventing liver disease in a human patient obtaining nutritional support through PN. The method comprises intravenous administration of an effective amount of an omega-3-fatty acid emulsion to the patient, wherein the patient is not administered phytosterols or plant derived fatty acids, e.g. omega-6 fatty acids derived from a plant source, and wherein the administration of the omega-3-fatty acid emulsion to the patient is for a period greater than three weeks. Preferably, the administration is for a period of greater than six weeks. More preferably, the administration is for a period greater than three months.

Prevention Of Surgical Adhesions

View page
US Patent:
2010022, Sep 2, 2010
Filed:
Nov 18, 2009
Appl. No.:
12/620665
Inventors:
Mark Puder - Medfield MA,
Arin K. Greene - Wellesley MA,
Assignee:
CHILDREN'S MEDICAL CENTER CORPORATION - Boston MA
International Classification:
A61K 31/517
A61K 31/404
A61K 31/4439
A61K 31/44
A61P 17/02
A61P 17/00
A61P 35/00
US Classification:
5142664, 514414, 514338, 514350
Abstract:
The present invention relates to methods for treatment (particularly the prevention or suppression) of formation or reformation of adhesions, particularly in the peritoneal or pelvic cavities resulting from wound, surgery, infection, inflammation or trauma. The invention provides methods useful for inhibiting, suppressing or ameliorating adhesion formation in mammals, including humans wherein an individual is administered a compound selected from the group consisting of sunitinib malate, axitinib, semaxanib, sorafenib, ZD1839, and erlotinib. The invention applies to human and veterinary applications. The inventive method has been shown to be especially effective in preventing adhesion formation in the peritoneum following surgery.

Dietary Formulations And Methods For Treatment Of Inflammation And Other Disorders

View page
US Patent:
2010025, Oct 7, 2010
Filed:
May 27, 2008
Appl. No.:
12/602054
Inventors:
Mark Puder - Medfield MA,
Bruce Bistrian - Ipswich MA,
Assignee:
CHILDREN'S MEDICAL CENTER CORPORATION - Boston MA
BETH ISRAEL DEACONESS MEDICAL CENTER, INC. - Boston MA
International Classification:
A61K 31/201
A61P 3/00
A61P 29/00
US Classification:
514560
Abstract:
Dietary formulations in the form of an oil emulsion providing total enteral or parenteral nutrition, or in the form of food oil suitable for oral administration is provided. The formulations include about 2-60% by calories of a C20 or longer omega-3 fatty acid and about 0.05% to 1% by calories of arachidonic acid, where the formulation provides less than 1% of total calories from linoleic acid and alpha-linolenic acid, and where the fatty acids provide 5-60% of the total calories of said dietary formulation. Methods for treatment of diseases and disorders using the dietary formulations are also provided.
Mark Puder from Medfield, MA, age ~62 Get Report